Traders Buy Large Volume of Put Options on Myriad Genetics (MYGN)
Shares of Myriad Genetics (NASDAQ:MYGN) were the target of some unusual options trading activity on Tuesday. Stock investors purchased 432 put options on the company, Stock Ratings News reports. This represents an increase of approximately 194% compared to the average volume of 147 put options.
Several analysts have recently commented on the stock. Analysts at SunTrust raised their price target on shares of Myriad Genetics from $22.00 to $26.00 in a research note on Monday, July 14th. Separately, analysts at RBC Capital raised their price target on shares of Myriad Genetics from $31.00 to $40.00 in a research note on Monday, June 30th. They now have a “sector perform” rating on the stock. Finally, analysts at Macquarie reiterated a “neutral” rating on shares of Myriad Genetics in a research note on Thursday, June 5th. They now have a $36.00 price target on the stock, down previously from $38.00. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. Myriad Genetics currently has a consensus rating of “Hold” and an average target price of $35.34.
Myriad Genetics (NASDAQ:MYGN) traded up 1.91% on Tuesday, hitting $39.00. 1,817,394 shares of the company’s stock traded hands. Myriad Genetics has a one year low of $20.02 and a one year high of $42.50. The stock’s 50-day moving average is $37.69 and its 200-day moving average is $35.9. The company has a market cap of $2.918 billion and a price-to-earnings ratio of 16.23.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, August 12th. The company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.02. The company had revenue of $188.80 million for the quarter, compared to the consensus estimate of $187.68 million. Analysts expect that Myriad Genetics will post $2.39 EPS for the current fiscal year.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Receive News & Ratings for Myriad Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.